A series of cardiometabolic-related news items has been observed from FDA, Novo Nordisk, Altimmune, Lilly, and Insulet. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, Fractyl Health, and Roche. Below, FENIX provides highlights and insights for the respective news items.
Novo Nordisk hosted its Q1 ’26 earnings call and provided updates across its diabetes and obesity businesses (view press release; view slides). Of note, the company’s stock is up ~3% after raising its FY 2026 adjusted sales guidance to -4% to -12% (previously -5% to -13%), driven by a “best-in-class” US launch of Wegovy Pill and strong GLP-1RA demand in OUS markets. Below, FENIX provides highlights and insights from the Q1 ’26 earnings call.
A series of cardiometabolic-related news items has been observed by Pfizer, Madrigal Pharmaceuticals, Novo Nordisk, Vertex Pharmaceuticals, and Cytokinetics. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Amgen, Dexcom, Zealand Pharma, Esperion Therapeutics, Senseonics, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Lilly, Regeneron, Arrowhead Pharmaceuticals, and Senseonics. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Roche, Novo Nordisk, Hims & Hers, Sanofi, and Amgen. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Lilly aired a new Foundayo DTC ad on social media platforms (view Reddit post); Roche’s CT-388 has been given the INN of enicepatide, which is reflected in two Ph2 studies (view CT.gov record; view CT.gov record); and the CHMP agenda for this month’s meeting (April 20-23) has been released (view here). Below, FENIX provides highlights and insights on the respective news items.
A series of cardiometabolic-related news items has been observed from Lilly, Novo Nordisk, Pfizer, Abbott, and Novartis. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from FDA/Lilly, Novo Nordisk, Sana Biotechnology, and Corbus Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.